At cancer diagnosis, TNM stage and tumor molecular markers (MMR, BRAFV600E, or KRAS) did not differ significantly between patients with early-onset and patients with average-onset colon cancer (Table 1). This evidence concerns the gene KRAS and colonic neoplasm.